Trial Profile
EGFR [epidermal growth factor receptor] pathway modulation in patients with ductal carcinoma in situ of the breast.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Ductal carcinoma; Early breast cancer
- Focus Biomarker; Therapeutic Use
- 22 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Mar 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
- 24 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.